SSY GROUP (02005) obtained the production registration approval for the sustained-release tablets of Amisulpride hydrochloride (4mg) and other drugs.

SSY GROUP (02005) announces that SSY GROUP Limited (the Company, together with its subsidiaries, the Group) is pleased to announce the latest developments in the Group's product development: The Group is the first domestic enterprise to obtain the drug production registration certificate for fat soluble vitamin injection () (10ml) from the China National Medical Products Administration (NMPA), belonging to the Class 3 chemical drugs, deemed equivalent through consistency evaluation. This product is mainly used for children under 11 years old and infants as a supplement for intravenous nutrition to meet the daily requirements for fat-soluble vitamins A, D2, E, and K1. The Group has obtained the drug production registration certificate for metformin hydrochloride tablets (0.5g and 0.25g) from the NMPA, belonging to the Class 4 chemical drugs, deemed equivalent through consistency evaluation. This product is mainly used for the treatment of type 2 diabetes that is ineffective with diet and exercise control of blood sugar. The Group has obtained the drug production registration certificate for doxazosin mesylate sustained-release tablets (4mg) from the NMPA, belonging to the Class 4 chemical drugs, deemed equivalent through consistency evaluation. This product is mainly used for symptomatic treatment of benign prostatic hyperplasia and treatment of hypertension. As mentioned in the Company's announcement dated April 8, 2024, the doxazosin mesylate active pharmaceutical ingredient of the Group has been approved by the NMPA for registration as a raw material for use in marketed formulations.